Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 294.25 GBp
Change Today +3.25 / 1.12%
Volume 32.1K
As of 7:50 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

skyepharma plc (SKP) Snapshot

300.00 GBp
Previous Close
291.00 GBp
Day High
300.00 GBp
Day Low
289.00 GBp
52 Week High
12/1/14 - 377.50 GBp
52 Week Low
08/1/14 - 229.50 GBp
Market Cap
Average Volume 10 Days
-0.20 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for SKYEPHARMA PLC (SKP)

Related News

No related news articles were found.

skyepharma plc (SKP) Related Businessweek News

No Related Businessweek News Found

skyepharma plc (SKP) Details

Skyepharma PLC develops and sells oral and inhalation pharmaceutical products. The company’s inhalation products include flutiform, a multi-dose pressurized metered dose inhaler for the treatment of bronchial asthma; Anoro Ellipta and Incruse Ellipta multi-dose dry powder inhalers for the treatment of chronic obstructive pulmonary disease (COPD); and Relvar Ellipta/Breo Ellipta multi-dose dry powder inhaler for the treatment of asthma and COPD. It also offers Solaraze, a topical gel treatment for actinic keratosis; and Exparel, a bupivacaine injectable product for post-surgical pain management. The company’s oral drug delivery products comprise Paxil CR, an anti-depressant; Sular, a calcium channel blocker antihypertensive agent; Xatral OD, a selective alpha blocker for the treatment of BPH (urinary symptoms); Requip for Parkinson’s disease; Diclofenacratiopharm uno, a dual release diclofenac sodium formulation for pain/inflammation; and ZYFLO CR, an extended-release formulation of the oral asthma drug zileuton. Its oral drug delivery products also comprise Madopar DR, an oral treatment for Parkinson’s disease; Lodotra, a night-time release formulation of low dose prednisone for the treatment of morning stiffness associated with rheumatoid arthritis; Triglide, an oral treatment for elevated blood lipid disorders; and Coruno for the oral treatment of chronic angina pectoris. The company has partnerships with various companies, including GlaxoSmithKline, Sanofi, Mundipharma, and Kyorin worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.

92 Employees
Last Reported Date: 04/10/15
Founded in 1910

skyepharma plc (SKP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 567.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 74.0K GBP
Compensation as of Fiscal Year 2013.

skyepharma plc (SKP) Key Developments

Skyepharma Seeks Acquisitions

Skyepharma PLC (LSE:SKP) is seeking acquisitions. Barclays has provided Skyepharma a £25 million revolving credit facility. The funding from Barclays will be used for general corporate purposes including acquisitions.

Skyepharma PLC, Annual General Meeting, May 12, 2015

Skyepharma PLC, Annual General Meeting, May 12, 2015., at 10:30 GMT Standard Time. Location: offices of FTI Consulting.

SkyePharma plc Reports Audited Consolidated Financial Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

SkyePharma plc reported audited consolidated financial results for the year ended December 31, 2014. For the year, revenue was £73.8 million against £62.6 million for the last year. Operating profit was £21.6 million against £13.6 million for the last year. Loss before tax was £9.9 million against £1.0 million for the last year. Total loss for the year attributable to the parent was £10.5 million against total net profit of £0.8 million for the last year. Diluted Loss per share was 12.3 pence against diluted earnings per share of 1.7 pence for the last year. Net cash generated by operating activities was £29.9 million against £14.2 million for the last year. Purchases of property, plant and equipment was £1.1 million against £2.4 million for the last year. Purchases of intangible assets were £1.8 million against £1.1 million for the last year. EBITDA was £25.0 million against £17.9 million a year ago. The increase in revenue from 2013 is mainly due to a higher level of milestone receipts, growth in flutiform supply and royalty revenues, increased revenue from a share of growing net sales of EXPAREL as well as the first EXPAREL sales milestone and a full year of rental income being recorded in respect of the Facility leased by Aenova following the lease renewal in December 2013. The company’s key objectives for 2015 are to: Grow overall revenue from approved products and pipeline product candidates; Continue to grow operating profit and generate cash from operations; The Board expects further substantial growth in revenues in 2015 compared with 2014 mainly from the products launched in the last three years, especially flutiform®, EXPAREL® and the GSK inhalation products. As a result of the additional investment, capital expenditure on flutiform® in 2015 is expected to total approximately £7 million to £9 million, and total capital expenditure in 2015 is forecast to be approximately £10 million to £12 million, including investment in R&D activities, IT improvement projects and potential investment in the Lyon Facility to improve efficiency and expand capabilities prior to the Facility returning to Skyepharma's management during 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKP:LN 294.25 GBp +3.25

SKP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $8.10 USD -0.39
Depomed Inc $20.76 USD +0.51
Onxeo SA €5.38 EUR +0.05
Veloxis Pharmaceuticals A/S kr1.00 DKK -0.02
XenoPort Inc $6.21 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation SKP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYEPHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at